Market Cap | ₹3,145Cr |
ROE | 7.19% |
P/E Ratio(TTM) | 49.72 |
EPS(TTM) | 5.13 |
P/B Ratio | 2.49 |
Dividend Yield | 0.31% |
Industry P/E | 34.34 |
Book Value | 102.37 |
Debt to Equity | 0.61 |
Face Value | 2 |
Parent Organisation | Hikal Limited |
Managing Director | Mr. Sameer Hiremath |
NSE Symbol | HIKAL |
FUND NAME | AUM(%) |
---|---|
Tata Small Cap Fund Direct Growth | 0.92% |
Tata India Pharma & Healthcare Fund Direct Growth | 0.76% |
COMPANY | 52 WEEK | MARKET PRICE | P/E Ratio | |
---|---|---|---|---|
Divi's Laboratories | NA (0.00%) | 70.43 | ||
Neuland Laboratories | NA (0.00%) | 98.02 | ||
Jubilant Pharmova | NA (0.00%) | 35.29 | ||
Acutaas Chemicals | NA (0.00%) | 60.86 |